China Rare Disease Clinical Trials Market Size & Outlook
China rare disease clinical trials market, 2018-2030 (US$M)
Related Markets
China rare disease clinical trials market highlights
- The China rare disease clinical trials market generated a revenue of USD 273.1 million in 2023 and is expected to reach USD 577.9 million by 2030.
- The China market is expected to grow at a CAGR of 11.3% from 2024 to 2030.
- In terms of segment, phase ii was the largest revenue generating phase in 2023.
- Phase III is the most lucrative phase segment registering the fastest growth during the forecast period.
Rare disease clinical trials market data book summary
| Market revenue in 2023 | USD 273.1 million |
| Market revenue in 2030 | USD 577.9 million |
| Growth rate | 11.3% (CAGR from 2023 to 2030) |
| Largest segment | Phase ii |
| Fastest growing segment | Phase III |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Phase I, Phase II, Phase III, Phase IV |
| Key market players worldwide | Takeda Pharmaceutical Co Ltd, Roche Holding AG ADR, Pfizer Inc, AstraZeneca PLC, Novartis AG ADR, Labcorp Holdings Inc, IQVIA Holdings Inc, Charles River Laboratories International Inc, Icon PLC, PAREXEL |
Other key industry trends
- In terms of revenue, China accounted for 3.3% of the global rare disease clinical trials market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan rare disease clinical trials market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 577.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Rare Disease Clinical Trials Market Scope
Rare Disease Clinical Trials Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China rare disease clinical trials market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 42.66% in 2023. Horizon Databook has segmented the China rare disease clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
- China Rare Disease Clinical Trials Phase Outlook (Revenue, USD Million, 2018-2030)
- Phase I
- Phase II
- Phase III
- Phase IV
- Others
- China Rare Disease Clinical Trials Study Design Outlook (Revenue, USD Million, 2018-2030)
- Interventional trials
- Observational trials
- Expanded access trials
- China Rare Disease Clinical Trials Therapeutic Area Outlook (Revenue, USD Million, 2018-2030)
- Cardiovascular Disorders
- Neurological Disorders
- Infectious Disease
- Genetic Disorders
- Autoimmune and Inflammation
- Hematologic Disorders
- Musculoskeletal Disorders
- Others
Reasons to subscribe to China rare disease clinical trials market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China rare disease clinical trials market databook
-
Our clientele includes a mix of rare disease clinical trials market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China rare disease clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into China rare disease clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China rare disease clinical trials market size, by phase, 2018-2030 (US$M)
China Rare Disease Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
